LONG-TERM SURVIVAL OF DONOR-SPECIFIC PANCREATIC-ISLET XENOGRAFTS IN FULLY XENOGENEIC CHIMERAS (WF RAT-]B10 MOUSE)

被引:30
作者
ZENG, YJ [1 ]
RICORDI, C [1 ]
TZAKIS, A [1 ]
RILO, HLR [1 ]
CARROLL, PB [1 ]
STARZL, TE [1 ]
ILDSTAD, ST [1 ]
机构
[1] UNIV PITTSBURGH,DEPT SURG,DIV TRANSPLANTAT,BIOMED SCI TOWER W1556,PITTSBURGH,PA 15261
关键词
D O I
10.1097/00007890-199202010-00005
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
We recently reported that reconstitution of lethally irradiated B10 mouse recipients with 40 x 10(6) untreated WF rat bone marrow cells resulted in stable fully xenogeneic chimerism (WF rat --> B10 mouse). In these animals, the tolerance induced for skin xenografts was highly MHC specific in that donor-specific WF rat skin grafts were significantly prolonged while MHC-disparate third-party xenografts were rapidly rejected (median survival time [MST] = 9 days). We have now examined whether islet cell xenografts placed under the renal capsule of chimeras rendered diabetic with streptozotocin would be accepted and remain functional to maintain euglycemia. Animals were prepared, typed for chimerism at 6 weeks, and diabetes induced with streptozotocin. Donor-specific WF (Rt1A(u)) islet cell xenografts were significantly prolonged (MST > 180 days) in WF --> B 10 chimeras, while MHC-disparate third-party F344 rat (Rt1A1) grafts were rejected with a time course similar to unmanipulated B 10 mice (MST = 8 days). The transplanted donor-specific islet cells were functional to maintain euglycemia, since removal of the grafts at from 100 to 180 days in selected individual chimeras uniformly resulted in return of the diabetic state. These data suggest that donor-specific islet cell xenografts are accepted and remain functional in mice rendered tolerant to rat xenoantigens following bone marrow transplantation.
引用
收藏
页码:277 / 283
页数:7
相关论文
共 55 条
  • [1] ALEJANDRO R, 1987, TRANSPLANT P, V19, P2359
  • [2] XENOGENEIC TRANSPLANTATION - A REVIEW
    AUCHINCLOSS, H
    [J]. TRANSPLANTATION, 1988, 46 (01) : 1 - 20
  • [3] USE OF CRYOPRESERVED DONOR BONE-MARROW IN CADAVER KIDNEY ALLOGRAFT RECIPIENTS
    BARBER, WH
    DIETHELM, AG
    LASKOW, DA
    DEIERHOI, MH
    JULIAN, BA
    CURTIS, JJ
    [J]. TRANSPLANTATION, 1989, 47 (01) : 66 - 71
  • [4] BARKER C F, 1980, Diabetes, V29, P86
  • [5] BILLINGHAM RE, 1953, NATURE, V172, P606
  • [6] BOWEN K M, 1980, Diabetes, V29, P98
  • [7] BOYSE EA, 1970, NATURE, V227, P902
  • [8] CARIDIS DT, 1973, TRANSPLANT P, V5, P671
  • [9] PREVENTION OF ALLOGRAFT-REJECTION BY IMMUNIZATION WITH DONOR BLOOD DEPLETED OF IA-BEARING CELLS
    FAUSTMAN, D
    LACY, P
    DAVIE, J
    HAUPTFELD, V
    [J]. SCIENCE, 1982, 217 (4555) : 157 - 158
  • [10] PROLONGATION OF MURINE ISLET ALLOGRAFT SURVIVAL BY PRETREATMENT OF ISLETS WITH ANTIBODY DIRECTED TO IA DETERMINANTS
    FAUSTMAN, D
    HAUPTFELD, V
    LACY, P
    DAVIE, J
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA-BIOLOGICAL SCIENCES, 1981, 78 (08): : 5156 - 5159